FDAnews Drug Daily Bulletin
Feb. 1, 2005 | Vol. 2 No. 22
Neose, BioGeneriX Enter Protein Pact
Neose Technologies has signed an agreement giving BioGeneriX AG an option to license its GlycoPEGylation technology. The total potential value of the deal wasn't disclosed in a press release by Neose. The biopharmaceutical company did say, however, that it includes milestones worth up to $61.5 million and unspecified upfront payments and royalties. The agreement aims to use the Neose technology to develop a "long-acting, next generation version of a currently marketed therapeutic protein," according to Neose.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.